CIBC Private Wealth Group LLC Buys 2,954 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

CIBC Private Wealth Group LLC increased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 137.1% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,108 shares of the biotechnology company’s stock after acquiring an additional 2,954 shares during the period. CIBC Private Wealth Group LLC’s holdings in ADMA Biologics were worth $95,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. National Bank of Canada FI acquired a new position in shares of ADMA Biologics during the 3rd quarter worth approximately $35,000. GAMMA Investing LLC increased its holdings in ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after buying an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics during the fourth quarter worth $35,000. Vision Financial Markets LLC acquired a new stake in ADMA Biologics in the fourth quarter valued at $51,000. Finally, AlphaQuest LLC bought a new position in shares of ADMA Biologics in the 4th quarter valued at about $84,000. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Trading Down 2.9 %

Shares of ADMA Biologics stock opened at $17.86 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business has a fifty day simple moving average of $17.55 and a two-hundred day simple moving average of $18.16. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of 63.79 and a beta of 0.53.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.